In 2010, Pharmaceutical Research and Manufacturers of America (PhRMA) members spending on R&D grew 6.5% to $49.4 billion. R&D spending by the total biopharmaceutical industry grew an estimated 2.3% to $67.4 billion. PhRMA members’ domestic R&D spending rose 5.7% to $37,371.0 million, while foreign spending increased 8.7% to $12,047.4 million. As a percentage of sales, domestic R&D was 21% and total R&D was 17%. In 2009, licensed-in R&D comprised 17.9% of domestic R&D spending. Also in 2009, Prehuman/Preclinical, Phase I, Phase II, Phase III, Approval and Phase IV accounted for 25%, 8%, 15%, 35%, 4% and 11% of R&D spending, respectively. PhRMA members’ biologics/biotech R&D spending in 2009 was $12,105.6 million, or 26% of R&D expenditures. R&D personnel at PhRMA members in 2009 consisted of 69,707 R&D staff and 9,243 “supported R&D nonstaff.” R&D staff percentage by function was: 29% for Prehuman/Preclinical, 7% for Phase 1, 12% for Phase II, 22% for Phase III, 5% for Approval and 11% for Phase IV.

Source: PhRMA